Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.
Michael L. Maitland
Consultant or Advisory Role - Astellas Pharma
Sai-Hong Ignatius Ou
No relevant relationships to disclose
Anthony W. Tolcher
Consultant or Advisory Role - Astellas Pharma
Patricia LoRusso
Consultant or Advisory Role - Astellas Pharma
Erkut Bahceci
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Howard A Ball
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Jung Wook Park
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Geoff Yuen
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Luana Pesco Koplowitz
Employment or Leadership Position - Duck Flats Pharma
Consultant or Advisory Role - Astellas Pharma
Tianhong Li
Consultant or Advisory Role - Astellas Pharma